Results 111 to 120 of about 111,238 (263)

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner   +5 more
wiley   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove   +4 more
wiley   +1 more source

Boerhaave Syndrome in the Intensive Care Unit: A Diagnostic Challenge. [PDF]

open access: yesCureus
Marques M   +4 more
europepmc   +1 more source

Awareness of the Black Triangle Scheme among healthcare professionals and consumers in Australia: A mixed‐methods study exploring reporting intentions and suggested improvements

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The Black Triangle Scheme, introduced in 2018 in Australia, does not appear to have increased the quantity of adverse drug event (ADE) reports. This study evaluated healthcare professionals' (HCPs') and consumers' awareness of the scheme, its influence on intentions for future ADE reporting, and suggested improvements.
Eyob Alemayehu Gebreyohannes   +7 more
wiley   +1 more source

Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear.
Ethan J. Cannon   +7 more
wiley   +1 more source

Flexible working and professional relationships in schools: An ecological approach

open access: yesBritish Educational Research Journal, EarlyView.
Abstract In English schools, the policy environment has recently moved considerably in favour of teachers taking planning, preparation and assessment (PPA) time away from the school site as one approach to flexible working in support of teacher retention.
Victoria Cook   +3 more
wiley   +1 more source

Biographies, ontological security and the socio‐spatial politics shaping teachers' mobility in remote Australia

open access: yesBritish Educational Research Journal, EarlyView.
Abstract The global teacher shortage continues to intensify, with disparate impacts across geographic and socio‐economic communities. In Queensland, Australia, where this study originates, post‐COVID teacher shortages have intensified workforce pressures, leaving several regional, rural and remote schools as some of the ‘hardest‐to‐staff’ in the ...
Matthew Readette   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy